Targeted Therapy of Pyrrolo[2,3-D]Pyrimidine Antifolates in a Syngeneic Mouse Model of High Grade Serous Ovarian Cancer
AssigneesDuquesne University of the Holy Spirit, Wayne State University
InventorsAleem Gangjee, Larry H. Matherly
Life of this patent
Estimating the term…
Abstract
A method of inhibiting M2-like macrophages in a patient is provided comprising administering to a patient having ovarian cancer a therapeutically effective amount of a FRB-transported C1 inhibitor compound having selective efficacy to FRβ expressing tumor cells. The method includes wherein the FRB-transported C1 inhibitor compound is a substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitor compound having selective efficacy to FRβ expressing tumor cells. The present invention provides a method for targeting both the tumor and the tumor microenvironment with the FRB-transported C1 inhibitor compounds.
Claims22
A method of inhibiting M2-like macrophages in a patient comprising administering to a patient having ovarian cancer a therapeutically effective amount of a substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitor having selective efficacy to FRβ expressing tumor cells.
A method of inhibiting M2-like macrophages in a patient comprising administering to a patient having ovarian cancer a therapeutically effective amount of a composition comprising a compound that is a substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitor having selective efficacy to FRβ expressing tumor cells, and an acceptable pharmaceutical carrier.
A method of inhibiting M2-like macrophages in a patient comprising administering to a patient having ovarian cancer a therapeutically effective amount of a FRβ-transported C1 inhibitor compound having selective efficacy to FRβ expressing tumor cells.
A method of inhibiting M2-like macrophages in a patient comprising administering to a patient having ovarian cancer a therapeutically effective amount of a composition comprising a FRβ-transported C1 inhibitor compound having selective efficacy to FRβ expressing tumor cells and a pharmaceutically acceptable carrier.
A FRβ-transported C1 inhibitor compound having selective efficacy to FRβ expressing tumor cells for use in inhibiting M2-like macrophages for treating a patient having ovarian cancer.
Dependencies are inferred from the claim text.